**Executive Summary**
The Indian Pharmacopoeia Commission (IPC) hosted a National Conference on June 24, 2026, to facilitate the awareness and implementation of new blood and blood component standards introduced in the Indian Pharmacopoeia (IP) 2026. This edition marks the first time a pharmacopoeia has established exclusive standards for these components, aiming to strengthen transfusion safety and regulatory compliance. The event served as a critical capacity-building platform for over 160 stakeholders to prepare for the effective adoption of these updated monographs.
**Key Points / Main Content**
**IP 2026 Standards and Innovation**
* IP 2026 introduces exclusive pharmacopoeial standards for blood and blood components, a global first among pharmacopoeias.
* The new monographs are designed to align with contemporary scientific developments and both national and international regulatory requirements.
* The standards focus on enhancing quality assurance, patient safety, and the efficacy of blood products across the country.
**Conference Proceedings and Participation**
* The conference was attended by over 160 professionals, including blood centre staff, quality control officers, and haemovigilance experts.
* Represented states included Uttar Pradesh, Rajasthan, Uttarakhand, Haryana, Punjab, and Madhya Pradesh.
* Technical sessions addressed various topics: regulatory requirements, rational use of blood, plasma quality, the National Formulary of India (NFI), and the Haemovigilance Programme of India (HvPI).
**Strategic Objectives**
* Stakeholders engaged in panel discussions to deliberate on implementation strategies and emerging regulatory expectations.
* The initiative emphasizes a shared commitment to ensuring the quality, safety, and availability of blood to strengthen healthcare delivery.
* The IPC utilized the platform for stakeholder engagement to ensure preparedness for the transition to IP 2026 standards.
**Impact Analysis**
**Blood Centre Professionals (including QA/QC Officers)**
**Impact**
These professionals are now governed by new, exclusive pharmacopoeial monographs that dictate the quality and safety protocols for blood and its components.
**Action Required**
They must adopt the IP 2026 standards, update their quality assurance processes, and ensure all transfusion services comply with the new technical requirements.
**State Licensing Authorities and Regulators**
**Impact**
Regulators must oversee a shift in compliance standards as the legal benchmarks for blood quality have been updated and expanded in the IP 2026.
**Action Required**
They need to participate in implementation strategy deliberations and enforce the new regulatory expectations during inspections and licensing.
**Government Health Officials**
**Impact**
Officials from the six participating states are responsible for the broader administrative and policy support required to integrate these standards into regional healthcare delivery.
**Action Required**
They must work collectively with the IPC and blood centres to ensure the safety and availability of blood components while safeguarding patient welfare.
Key Entities Referenced
Indian Pharmacopoeia (IP) 2026: The regulatory document establishing new, exclusive pharmacopoeial standards and monographs for blood and blood components in India.
Indian Pharmacopoeia Commission (IPC): The autonomous institution under the Ministry of Health and Family Welfare responsible for setting standards for drugs and organizing the national conference for stakeholder adoption.
Haemovigilance Programme of India (HvPI): A national initiative focused on monitoring the safety of blood transfusion, identified as a key component for implementing the new IP 2026 standards.
National Formulary of India (NFI): A referenced policy document used in conjunction with pharmacopoeial standards to ensure the rational use of medicines and blood products.
Uttar Pradesh, Rajasthan, Uttarakhand, Haryana, Punjab, and Madhya Pradesh: The primary group of states whose health officials and regulators participated in the deliberations for implementing the new blood quality standards.
Ministry of Health and Family Welfare
IPC Organizes National Conference on Ensuring
Quality of Blood and Blood Components through
IP 2026 Standards
IP 2026 Establishes Exclusive Standards for Blood and Blood
Components, a First Among Pharmacopoeias
Conference Facilitates Stakeholder Preparedness for
Adoption of New Pharmacopoeial Standards for Blood and
Blood Components
Over 160 Blood Centre Professionals, Regulators and Health
Officials from Six States Participate in Deliberations on
Strengthening Blood Quality and Safety
प्रव तथ: 24 JUN 2026 9:01PM by PIB Delhi
The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health
and Family Welfare, Government of India, organized a National Conference on “Ensuring Quality of
Blood and Blood Components through IP 2026” at its campus in Ghaziabad on June 24, 2026, to facilitate
awareness and implementation of the newly introduced blood and blood component monographs in the
Indian Pharmacopoeia (IP) 2026.
The conference brought together over 160 participants, including blood centre professionals, quality
assurance and quality control officers, State Licensing Authorities, haemovigilance experts, and
government health officials from Uttar Pradesh, Rajasthan, Uttarakhand, Haryana, Punjab, and Madhya
Pradesh.
The inaugural session was addressed by Shri Harsh Mangla, Joint Secretary (Drug and Food Regulation),
Department of Health and Family Welfare, Government of India, virtually. He appreciated IPC's efforts in
introducing pharmacopoeial standards for blood and blood components in IP 2026 (exclusively), not
present in any other pharmacopoeia. He also motivated all stakeholders to work collectively in moving
forward to our shared commitment of ensuring the quality, safety, and availability of blood and blood
components to strengthen healthcare delivery and safeguard patient welfare.Dr. G. N. Singh, Advisor to the Chief Minister of Uttar Pradesh and Former Secretary-cum-Scientific
Director, IPC, also graced the inaugural session. The programme commenced with a welcome address by
Dr. Jai Prakash, Senior Principal Scientific Officer, IPC, followed by introductory remarks from Dr. V.
Kalaiselvan, Secretary-cum-Scientific Director, IPC.
Addressing the participants, Dr. V. Kalaiselvan highlighted the significance of the newly incorporated
standards for blood and blood components in IP 2026, emphasizing their role in strengthening quality
assurance, patient safety, and regulatory compliance in transfusion services. He noted that the standards
are aligned with contemporary scientific developments and national and international regulatory
requirements.
The conference featured technical sessions on IP 2026 standards for blood and blood components,
regulatory requirements, rational use of blood, plasma quality, the National Formulary of India (NFI), the
Haemovigilance Programme of India (HvPI), and IP Online. A panel discussion involving experts from
IPC, State Licensing Authorities, HvPI, and transfusion medicine institutions deliberated on
implementation strategies and emerging regulatory expectations.The conference served as a platform for stakeholder engagement and capacity building, enabling blood
centres to prepare for the effective adoption of IP 2026 standards. Participants reaffirmed their
commitment to implementing the updated standards to further enhance the quality, safety, and efficacy of
blood and blood components across the country.
***
SR
HFW/IPC’s National Conference on Ensuring Quality of Blood and Blood Components /24June 2026/2
(रलीज़ आईडी: 2277579) आगंतुक पटल : 287
इस वज्ञ को इन भाषाओ ंम पढ़: Tamil